Meeting
2016 ASCO Annual Meeting
Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).
Authors
Anne C. Chiang
Yale Cancer Center, New Haven, CT
Anne C. Chiang , Charles M. Rudin , Alexander I. Spira , Robert M. Jotte , Shirish M. Gadgeel , Alain C. Mita , Lowell L. Hart , William Larry Gluck , Stephen V. Liu , Ann M. Kapoun , Lu Xu , Dawn Hill , Lei Zhou , Jakob Dupont , David R. Spigel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01859741
Citation
J Clin Oncol 34, 2016 (suppl; abstr 8564)
DOI
10.1200/JCO.2016.34.15_suppl.8564
Abstract #
8564
Poster Bd #
192
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).
First Author: Maria Catherine Pietanza
Poster
2023 ASCO Annual Meeting
Updated safety and efficacy results of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) from a phase II trial.
First Author: Dawei Chen
Poster
2022 ASCO Annual Meeting
Safety and efficacy of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): The results from a phase II single-arm trial.
First Author: Dawei Chen
Poster
2021 ASCO Annual Meeting
Efficacy and safety analysis of anlotinib combined with etoposide plus cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (SCLC): The final results from a phase II single-arm trial.
First Author: Tiandong Kong